Anti-MUC1 nano-aptamers for triple-negative breast cancer imaging by single-photon emission computed tomography in inducted animals: Initial considerations

International Journal of Nanomedicine

Volumn 12, Issue , 2017, Pages 53-60

  Do Carmo, Fagner Santos ^a,b   Ricci Junior, Eduardo ^c   Cerqueira Coutinho, Cristal ^c   Albernaz, Marta De Souza ^a,c   Bernardes, Emerson Soares ^d   Missailidis, Sotiris ^e   Santos Oliveira, Ralph ^b  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Nuclear Engineering Institute   (Brazil)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d INSTITUTO DE PESQUISAS ENERGÉTICAS E NUCLEARES   (Brazil)

^e INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Aptamer; Cancer control; Imaging; Nuclear medicine; Radiopharmacy

Indexed keywords

APTAMER; BIOLOGICAL MARKER; MUCIN 1; NANORADIOPHARMACEUTICAL AGENT; POLYGLACTIN; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; UNCLASSIFIED DRUG; MUC1 PROTEIN, HUMAN; NANOPARTICLE; PEPTIDE APTAMER; POLYMER; TECHNETIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CANCER DIAGNOSIS; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG SCREENING; EARLY CANCER DIAGNOSIS; FEMALE; GENE OVEREXPRESSION; IN VIVO STUDY; INTESTINE LEVEL; ISOTOPE LABELING; KIDNEY LEVEL; LIVER LEVEL; MOUSE; MUC1 GENE; NANOPHARMACEUTICS; NONHUMAN; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY-COMPUTED TOMOGRAPHY; SPLEEN LEVEL; TISSUE LEVEL; TRIPLE NEGATIVE BREAST CANCER; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DIAGNOSTIC IMAGING; HUMAN; METABOLISM; PROCEDURES; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; APTAMERS, PEPTIDE; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; DYNAMIC LIGHT SCATTERING; FEMALE; HUMANS; MICE, INBRED BALB C; MUCIN-1; NANOPARTICLES; POLYMERS; RADIOPHARMACEUTICALS; TECHNETIUM; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TRIPLE NEGATIVE BREAST NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85007605349     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S118482     Document Type: Article

References (43)

1. GLOBOCAN 2012: cancer incidence and mortality worldwide in 2012-IARC; 2012. Available from: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx. Accessed October 10, 2016.
2. Chappuis P, Rosenblatt J, Foulkes W. The influence of familial and hereditary factors on the prognosis of breast cancer. Ann Oncol. 1999;10(10):1163-1170.
3. Sorlie T. Molecular portraits of breast cancer: tumors subtypes as distinct disease entities. Eur J Cancer. 2004;40(18):2667-2675.
4. Jemal A, Center MM, Ward E, Thun MJ. Cancer occurrence. Methods Mol Biol. 2009;471:3-29.
5. Carey LA, Perou CM, Livasy CA. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492-502.
6. Reis-Filho JS, Westbury C, Pierga JY. The impact of expression, profiling on prognostic and predictive testing in breast cancer. J Clin Pathol. 2006;59(3):225-231.
7. DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64(1):52-62.
8. Chabalier C, Lamare C, Racca C, Privat M, Valette A, Larminat F. BRCA1 down regulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle. 2006;5(9):1001-1007.
9. Jeffrey SS, Fero MJ, Børresen-Dale AL, Botstein D. Expression array technology in the diagnosis and treatment of breast cancer. Mol Interv. 2002;2(2):101-109.
10. Dong M, How T, Kirkbride KC, et al. The type IIITGF-β receptor suppresses breast cancer progression. J Clin Invest. 2007;117:206-217.
11. Gender SJ, Spicer AP. Epithelial mucin genes. Annu Rev Physiol. 1995;57:607-634.
12. Gender SJ. MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia. 2001;6(3):339-353.
13. Girling A, Bartkova J, Burchell J, Gendler S, Gillett C, Taylor-Papadimitriou J. A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas. Int J Cancer. 1989;43(6):1072-1076.
14. Ho SB, Niehans GA, Lyftogt C, et al. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res. 1993;53:641-651.
15. Zhang YM, Liu N, Zhu ZH, Rusckowski M, Hnatowich DJ. Influence of different chelators (HYNIC, MAG3 and DTPA) on tumor cell accumulation and mouse biodistribution of technetium-99m labeled antisense DNA. Eur J Nucl Med. 2000;27(11):1700-1707.
16. Taylor-Papadimitriou J, Burchell J, Miles DW, Dalziel M. MUC1 and cancer. Biochim. Biophys. Acta. 1999;1455(2-3):301-313.
17. Vlad AM, Diaconu I, Gantt KR. MUC1 in endometriosis and ovarian cancer. Immunol Res. 2006;36(1-3):229-236.
18. Ferreira CSM, Matthews C, Missailidis S. DNA aptamers that bind to Muc1 tumour marker: design and characterization of Muc1-binding single stranded DNA aptamers. Tumour Biol. 2006;27(6):289-301.
19. Ferreira CSM, Papamichael K, Guilbault G, Schwarzacher T, Gariepy J, Missailidis S. DNA aptamers against Muc1: design of aptamer-antibody sandwich ELISA for early tumour diagnosis. Anal Bioanal Chem. 2008;390(4):1618-2642.
20. Chopra A, Shukla R, Sharma TK. Aptamers as an emerging player in biology. Aptamers Syn Antibodies. 2014;1(1):1-11.
21. Borbas KE, Ferreira CS, Perkins A, Bruce JI, Missailidis S. Design and synthesis of mono-and multimeric targeted radiopharmaceuticals based on novel cyclen ligands coupled to anti-MUC1 aptamers for the diagnostic imaging and targeted radiotherapy of cancer. Bioconjug Chem. 2007;18(4):1205-1212.
22. Pieve CD, Perkins AC, Missailidis S. Anti-Muc1 aptamers: radiolabelling with (99m)Tc and biodistribution in Mcf-7 tumour-bearing mice. Nucl Med Biol. 2009;36(6):703-710.
23. Da Pieve C, Blackshaw E, Missailidis S, Perkins AC. PEGylation and biodistribution of an anti-MUC1 aptamer in MCF-7 tumor-bearing mice. Bioconjug Chem. 2012;23(7):1377-1381.
24. Ferreira CS, Cheung MC, Missailidis S, Bisland S, Gariépy J. Phototoxic aptamers selectively enter and kill epithelial cancer cells. Nucleic Acids Res. 2009;37(3):866-876.
25. Hu Y, Duan J, Zhan Q, Wang F, Lu X, Yang XD. Novel MUC1 aptamer selectively delivers cytotoxic agent to cancer cells in vitro. PLoS One. 2012;7(2):e31970.
26. Sá LT, Simmons S, Missailidis S, da Silva MI, Santos-Oliveira R. Aptamer-based nanoparticles for cancer targeting. J Drug Target. 2013;21(5):427-434.
27. Yu C, Hu Y, Duan J, et al. Novel aptamer-nanoparticle bioconjugates enhances delivery of anticancer drug to MUC1-positive cancer cells in vitro. PloS One. 2011;6:e24077.
28. Hamoudeh M, Kamleh MA, Diab R, Fessi H. Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer. Adv Drug Deliv Rev. 2008;60:(2)1329-1346.
29. RobilottaCecil C. A tomografia por emissçao de pósitrons: uma nova modalidade na medicina nuclear brasileira. Ver Panam Salud Publica [Positron emission tomography: a new modality in Brazilian nuclear medicine]. V 20, n. 2/3; 2006. Available from: http://journal.paho.org/uploads/1162234592.pdf. Acesso em 05 de março de 2016. Portuguese.
30. Tonin RS. Cintilografia e PET/CT nas neoplasias malignas [Scintigraphy and PET/CT in malignant neoplasms]. Porto Alegre, Rio Grande do Sul: UFRS; 2011. Portuguese.
31. Santos-Oliveira R. Nanoradiopharmaceuticals: is that the future for nuclear medicine? Curr Radiopharm. 2011;4(2):140-143.
32. Sarcinelli MA. Desenvolvimento de Nanopartícula de Poli(Ácido Lático) contendo Anticorpo Monoclonal marcada com 99mTc para o Diagnóstico Precoce e Tratamento Eficaz do Câncer de Mama [Tese de D.Sc]. Rio de Janeiro, RJ: IMA/UFRJ; 2014. Portuguese.
33. Albernaz M de S, Ospina CA, Rossi AM, Santos-Oliveira R. Radiolabelled nano hydroxyapatite with 99mTc: perspectives to nano radiopharmaceuticals construction. Artif Cells Nanomed Biotechnol. 2014;42(2):88-91.
34. Pinto SR, Sarcinelle MA, de Souza Albernaz M, et al. In vivo studies: comparing the administration via and the impact on the biodistribution of radiopharmaceuticals. Nucl Med Biol. 2014;41(9):772-774.
35. Zhou J, Satheesan S, Li H, et al. Cell-specific RNA aptamer against human CCR5 specifically targets HIV-1 susceptible cells and inhibits HIV-1 infectivity. Chem Biol. 2015;22(3):379-390.
36. Baek JS, Kim JH, Park JS, Cho CW. Modification of paclitaxel-loaded solid lipid nanoparticles with 2-hydroxypropyl-b-ciclodextrin enhances absorption and reduces nephrotoxicity associated with intravenous injection. Int J Nanomedicine. 2015;10:5397-5405.
37. Xu F, Liu F, Zhao H, An G, Feng G. Prognostic significance of MUC1 in various human epithelial cancer: a meta-analysis. Medicine. 2015;94(50):e2286.
38. Gouyer V, Dubuquoy L, Robbe-Masselot C, et al. Delivery of a mucin domain enriched in cysteine residues strengthens the intestinal mucous barrier. Sci Rep. 2015;15(5):9577.
39. Kim GE, Bae HI, Park HU, et al. Aberrant expression of MUC5AC and MUC6 gastric mucins and sialylTn antigen in intraepithelial neoplasm of the pancreas. Gastroenterology. 2002;123(4):1052-1060.
40. Corfield A, Myerscough N, Longman R, Sylvester P, Arul S, Pignatelli M. Mucins and mucosal protection in the gastrointestinal tract: news prospects for mucins in the phatology of gastrointestinal disease. Gut. 2000;47(4):589-594.
41. Lee MJ, Lee HS, Kim WH, Choi Y, Yang M. Expression of mucins and cytokeratins in primary carcinomas of the digestive system. Mod Pathol. 2003;16(5):403-410.
42. Anselmo AC, Gupta V, Zern BJ, et al. Delivering nanoparticles to lungs while avoiding liver and spleen through adsorption on red blood cells. ACS Nano. 2013;7(12):11129-11137.
43. Blanco E, Shen H, Ferrari M. Nanoparticle rational design implementation for overcoming delivery barriers. Nat Biotechnol. 2015;33:941-951.